First Chinese Product Development Partnership for TB, Malaria and HIV/AIDS Announced

Today on World TB Day, the International Scientific Exchange Foundation of China (ISEFC), announced the signing of a Memorandum of Understanding with the Global Alliance for TB Drug Development (TB Alliance) to establish the Global Health R&D Center of China (GHRC). This innovative center will focus on the development of treatments for the world’s leading infectious disease killers—tuberculosis, malaria, and HIV/AIDS.

This is a ground-breaking partnership that will create the first Chinese not-for profit product development partnership (PDP), which is a class of partnerships that bridge public- and private-sector interests to develop pharmaceutical products for neglected diseases. Hui Yongzheng, the Chairman of the ISEFC Committee, comments, “It will be a center of excellence, which can harness international innovation and China’s growing research and development capabilities to meet the public health needs of the Chinese people and the rest of the world.”

This announcement comes on the heels of news from the “Fifth National Tuberculosis Epidemiology Site Survey” released by China’s Ministry of Health that over 500 million Chinese are infected with Mycobacterium tuberculosis which is 45% of the country’s population. In terms of morbidity and mortality, 1.3 million Chinese develop active TB and 150,000 deaths occur each year. “The creation of the GHRC will help to ensure that these promising new therapies will be developed and available to TB patients in China,” says Dr. Mel Spigelman, President and CEO of the TB Alliance, which has contributed significantly to the largest pipeline of TB drugs in history.

The GHRC is poised to be another great ally in finding treatments that will help the fight against TB and other diseases aiding in the alleviation of suffering of millions of patients around the world.

For full press release, click here.

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...